Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain
May 14, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 14, 2024 (GLOBE NEWSWIRE) -- Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain ...
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
March 19, 2024 08:00 ET
|
Ludwig Enterprises, Inc.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
March 06, 2024 08:00 ET
|
Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent
Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Forecasts to 2034
January 25, 2024 09:04 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The...
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
January 22, 2024 21:28 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive analysis within...